|1.||Nakajima, Kenji: 8 articles (03/2015 - 02/2006)|
|2.||Nakajima, Yoshiki: 3 articles (03/2015 - 01/2009)|
|3.||Minematsu, Masaharu: 3 articles (08/2008 - 02/2006)|
|4.||Tsujiwaki, Satomi: 2 articles (03/2015 - 08/2014)|
|5.||Miyamoto, Yuuichi: 2 articles (04/2008 - 10/2007)|
|6.||Brix, A: 1 article (01/2014)|
|7.||Sanders, J M: 1 article (01/2014)|
|8.||Dunnick, June K: 1 article (01/2014)|
|9.||Travlos, G S: 1 article (01/2014)|
|10.||Yokoyama, Akiko: 1 article (01/2009)|
06/01/2006 - "These studies are the first to show that transient inhibition of BHMT in vivo causes transient hyperhomocysteinemia, and that dimethylsulfoniopropionate can reduce a post-Met load rise in tHcy."
02/01/2006 - "Hyperhomocysteinemia can be ameliorated by dimethylsulfoniopropionate in place of folic acid in mice."
|2.||Parkinson Disease (Parkinson's Disease)
02/01/2006 - "The effect of dimethylsulfoniopropionate (DMSP) on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease (PD) of mice was examined for 5 d. "
02/01/2006 - "Ameliorating effect of dimethylsulfoniopropionate on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease of mice."
08/01/2008 - "The induction of Parkinson's disease (PD) in senescence-accelerated mice (SAMP8) by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and the effects of dimethylsulfoniopropionate (DMSP) on induced PD model mice of SAMP8 were investigated for 5 wk. After many trials, the tail suspension test determining the PD symptoms indicated that an appropriate amount of MPTP clearly raises the SAMP8 mice to the PD-model mice. "
08/01/2008 - "Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine."
03/05/2002 - "This study was designed to evaluate the effect of BPO and DMPT concentrations, along with their molar ratio, on the fracture toughness, fatigue strength, and residual monomer content of the experimental compositions. "
11/01/2003 - "We found that the Weibull mean fatigue lives for specimens fabricated using the DMPT, DMAL, and DMAO containing cements were 272,823, 453,551, and 583,396 cycles, respectively. "
03/05/2002 - "The results showed that fracture toughness and fatigue strength for the solution cements were comparable to Simplex P and were not significantly affected by the BPO concentration or the BPO:DMPT molar ratio; however, the highest DMPT concentration yielded significantly lower values for both variables. "
01/01/1992 - "To better understand this discrepancy in organotropism of the teratogenic and transplacental carcinogenic processes, the present study was undertaken to characterize the neoplasms induced in rat fetuses exposed to DMPT in utero. "
01/01/1992 - "Exposure to single intraperitoneal doses of DMPT on gestation day 20 did not produce a classic dose-response pattern: Minimal effects were observed with 10 mg DMPT/kg (occasional renal mesenchymal tumors and brain neoplasms), marked effects were observed with 30 mg DMPT/kg (lower incidence rate of most of the alterations observed with 1 mg/kg on gestation days 16, 18, and 20), and no effects were observed with 60 mg DMPT/kg. DMPT administered intraperitoneally at 1 mg/kg body weight on gestation days 16, 18, and 20 is an animal model of transplacental chemically induced renal neoplasms, which provide lesions with similarities to both intralobar nephrogenic rests and congenital mesoblastic nephroma of humans. "
|1.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|5.||Nerve Growth Factor (NGF)
|6.||Streptomycin (Streptomycin Sulfate)